Raltegravir is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated:Â Â
Raltegravir can be administered with or without food.
Raltegravir 400 mg film-coated tablets cannot be substituted with Raltegravir 25 mg and 100 mg chewable tablets.Â
Adults Â
Children and AdolescentsÂ
2 To less than 6 years of age:Â Â
Creatine kinase elevations were observed in subjects who received Raltegravir. Myopathy and rhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or rhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions.
Severe, potentially life-threatening and fatal skin reactions have been reported. This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis. Immediately discontinue treatment with Raltegravir and other suspect agents if severe hypersensitivity, severe rash, or rash with systemic symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver aminotransferases closely. Â
Monitor for Immune Reconstitution Syndrome.
Inform patients with phenylketonuria that the 100 mg and 25 mg chewable tablets contain phenylalanine.
Is raltegravir FDA approved?
Yes the medicine Raltegravir was approved by the FDA.
What class of drug is raltegravir?
Raltegravir belongs to the class of HIV integrase inhibitors.
When was raltegravir approved?
The FDA approved Raltegravir in 2007.
The Indian Generic Medicines is a Consultancy and Service company providing access to genuine generic medicines to patients all across the world. We also have own pharmacy named as Indian Generic Medicines which work under compliant distribution guidelines.
© 2025 Indian Generic Medicines. All rights reserved.
